Corporate Banner
Satellite Banner
Biomolecular Screening
Scientific Community
Become a Member | Sign in
Home>Resources>White Papers>This White Paper
  White Papers
Scientific News
Mass Spec Technology Drives Innovation Across the Biopharma Workflow
With greater resolving power, analytical speed, and accuracy, new mass spectrometry technology and techniques are infiltrating the biopharmaceuticals workflow.
Targeting Cannabinoid CB2 Receptors in the CNS
With endogenous cannabinoids considered as a potential target to combat CNS diseases, this article examines the role of CB2R could play in fighting some disorders.
Bacterial Genes Boost Current in Human Cells
Borrowing and tweaking bacterial genes to enhance electrical activity might treat heart, nervous system injury.
Less Frequent Cervical Cancer Screening
HPV-vaccinated women may only need one screening every 5 to 10 years with screening starting later in life.
Cocoa Compound Linked to Some Cardiovascular Biomarker Improvements
The study highlights the urgent need for large, long-term RCTs that improve understanding of how the short-term benefits of cocoa flavanol intake on cardiometabolic biomarkers may be translated into clinical outcomes.
Untangling a Cause of Memory Loss in Neurodegenerative Diseases
The mouse study identifies a possible therapeutic target for a family of disorders.
New Pathway for COPD Biomarker Development
A study from Philip Morris International has highlighted multi-lipid profiling as a potential new pathway for COPD biomarker development.
Stiffening a Blow to Cancer Cells
Researchers develop a way to predict how a tumor tissue's physical properties affect its response to chemotherapy drugs.
Anti-Cancer Drug Uses Tumour mRNA to Identify Responders
Phase I study of novel anti-cancer drug uses tumour mRNA expression to identify patients who will respond to the drug.
New Strategy for Choosing Cancer Drugs
Device can predict tumor responses by measuring cell growth after drug exposure.
Scroll Up
Scroll Down

The New Role of Academia in Drug Discovery and Development: New Thinking, New Competencies, New Results
Bookmark and Share

Kauffman Foundation

Five leaders in the medical innovation field released a white paper today titled The New Role of Academia in Drug Discovery and Development: New Thinking, New Competencies, New Results. This white paper reflects key recommendations from a July 2010 town hall meeting in Kansas City hosted by Friends of Cancer Research, Kansas Bioscience Authority, The University of Kansas Cancer Center, Ewing Marion Kauffman Foundation and Council for American Medical Innovation.

The white paper outlines how government, nonprofit organizations and academic institutions can define new models of working with the private sector to enhance drug development efforts and bring safer, more effective drugs to the market more efficiently. Recommendations for this new model are based on a series of expert panel discussions held during the town hall meeting.
"This call to action is the result of an extraordinary meeting of key policy makers, academics, industry leaders and the non-profit community, who understand the urgency for new collaborations in cancer research and drug development," said Roy A. Jensen, M.D., director of The University of Kansas Cancer Center. "As universities increasingly seek to commercialize their research, we need a new paradigm for drug discovery. The University of Kansas Cancer Center is proud to partner with these organizations to lead the way."

"Together, we can knock down barriers to scientific innovation, and, as we do that, we will accelerate our progress in the fight against diseases such as cancer," said Tom Thornton, president and CEO of the Kansas Bioscience Authority.

"We hope our nation's healthcare leaders and policymakers will study the insights and adopt the recommendations in this report. We can make groundbreaking progress in how scientific discoveries translate to patient healthcare if they do," said Lesa Mitchell, vice president of advancing innovation at the Kauffman Foundation.

"This white paper outlines critical steps toward much-needed increased interagency collaboration," said Dr. Ellen Sigal, Chair, Friends of Cancer Research. "The proposals discussed within this document aim to accelerate the process to help get scientific breakthroughs to patients. The message is clear; without collaboration among all agencies and academic centers, the full potential of biomedical research may be stifled."

"The Council for American Medical Innovation is pleased to have supported this ground breaking event examining the new role of academia in drug development," said Debra Lappin, President of the Council for American Medical Innovation. "The white paper reflects a rare dialogue among leaders across sectors and paves the way forward for the next generation of research, discovery and medical advances."

Further Information

Skyscraper Banner

Skyscraper Banner
Go to LabTube
Go to eposters
Access to the latest scientific news
Exclusive articles
Upload and share your posters on ePosters
Latest presentations and webinars
View a library of 1,800+ scientific and medical posters
3,500+ scientific and medical posters
A library of 2,500+ scientific videos on LabTube
5,100+ scientific videos